T HE SECRETION of anterior pituitary gonadotropins is under the control of the hypothalamic hormone LHRH (1, 2). Several studies have shown that the neurons that synthesize LHRH are innervated by multiple neuronal pathways, which use different neurotransmitter systems. It is via these pathways that extrahypothalamic structures may modify LHRH release and, consequently, modulate gonadotropin secretion (3, 4) . The study of the neurons that synthesize LHRH is made difficult by the peculiar anatomy of the LHRH system, which is composed of only a few hundred neurons scattered in the hypothalamic area.
A promising tool for the investigation of these interactions became available recently, when an immortalized line of LHRH-producing neurons (the GTl cell line) was developed; this was obtained by targeted tumorigenesis in transgenic mice (5). The three subclones of the GTl cells so far obtained (GTI-1, GTl-3, and GTl-7) (5) show the phenotypic characteristics of neuronal cells and synthesize and secrete abundant amounts of LHRH (5-7). If one assumes that these cell lines reflect the biological characteristics of physiological LHRH-synthesizing neurons, they may be used to extend our Maggi knowledge on the physiology of LHRH-secreting cells. Recently, it has been shown that the GTl cells possess the receptors for several families of neurotransmitters known to modify LHRH secretion, such as those for norepinephrine (8, 9) , dopamine (9, lo), y-aminobutyric acid (ll), excitatory amino acids (12, 13), endothelin (14), etc.
It is known that among the transmitters involved in the control of LHRH release, the endogenous opioid peptides dynorphin, play a particularly relevant role (1, (15) (16) (17) (18) . It has been repeatedly shown that opioid agonists (e.g. morphine) inhibit gonadotropin release, and that opioid antagonists (e.g. naloxone) stimulate LH output (19-21). However, little is known about the site where opioids act to modulate gonadotropin secretion. There is no clear-cut evidence on a possible direct effect of natural and synthetic opioids on LHRHproducing neurons, because of the methodological difficulty in studying LHRH neurons in viva. The majority of the reports available support the view that the effects of opioids on the LHRH-secreting system might be indirect, via the interaction with intermediate neuronal systems that influence LHRH secretion through the release of their specific neurotransmitters (18).
As no data are available on the presence of opioid receptors on the neurons synthesizing LHRH, it was felt to be of interest to verify whether opioid receptors might be present on GTl cells. To this purpose, the possible binding of the nonselective opioid ligand diprenorphine (DIP) on GTl-1 cells was first analyzed, using both membrane preparations and intact cells. As it is known that opioids exert their effects through the interaction with at least three subclasses of specific binding sites (named, respectively, /.L, 6, and K) (22,231, it 
Results
Studies on GTl-1 cell membrane preparations
Receptor binding experiments have shown the presence of specific binding of the opioid ligand 13H]DIP to crude membrane preparations obtained from GTI-1 cell homogenates. Such binding attains equilibrium in 30 min at 25 C and is totally inhibited by an excess (1 PM) of unlabeled nonselective opioid ligands such as bremazocine and naltrexone, which leave a low (5%) residual nonspecific binding (data not shown).
As illustrated in Fig. 1 and U50488H were used to inhibit the binding of f3HlDIP, respectively, to p-, 6, and K-receptors. Two concentrations of each selective ligand were used to obtain a submaximal and a maximal mask of their relative binding sites. The results show that at 1-nM concentrations, the three specific ligands had no significant inhibitory effect on [3HlDIP binding (Fig. 2) . At higher concentrations (100 no), only the specific Migand DPDPE inhibited (up to 60%) the specific binding of 13HlDIP to GTl-1 membranes (Fig. 2) . The pure p-and k-ligands DAGO and U50488H were practically ineffective in inhibiting 13HlDIP binding even at the higher concentration (Fig. 2) . These results may be indicative of the presence of only &opioid-binding sites on the membranes of GTl-1 cells.
The characteristics of the inhibitory effect of DPDPE on [3HlDIP binding were further investigated by heterologous displacement curves. The analysis of these curves shows that DPDPE inhibits the specific binding of 1 nM i3HlDIP on GTl-1 cell membranes in a dose-related fashion, with a Ki of 5.5 no and maximal inhibition (>90%) at the l-PM concentration (Fig. 3) . antagonist r3HlDIP was not changed in the presence of 100 mM NaCl (data not shown), whereas a significant increase in the IC,, of DPDPE was observed (Table 1) .
Studies on intact GTl-1 cells
To rule out the possibility that the results obtained might be due to artefacts linked to the mechanical disruption of membrane integrity and cytoskeletal ultrastructures during homogenization, the binding of [3HlDIP was also assessed in intact GTl-1 cells. The analysis of the saturation curve of [3HlDIP to intact GTl-1 cells shows that in these conditions, specific binding of the labeled ligand occurs; this is characterized by the same K, value (0.23 nM) previously observed in membrane preparations. The density of receptors labeled by t3H1DIP in intact cells appears to be 38 fmol/mg protein, corresponding to approximately 20,000 sites/cell, with a nonspecific binding of 5% (Fig. 4) . The binding of [3HlDIP to intact GTl-1 cells is presumably due to an interaction with receptors located on the cellular membrane (26) and not to internalization of the tracer. In fact, an acid wash (PBS, pH 3, for 6 mm at 4 Cl performed on intact GTl-1 cells previously incubated under standard conditions with 13HlDIP (see MatcriuZs and Methods) removes more than 85% of the f3H1DIP bound to these cells. Selective inhibition of the specific binding of [3H]DIP to intact GTl-1 cells also shows that only those ligands that bind preferentially the Z-opioid receptors (i.e. DPDPE) are able to inhibit the binding of the tracer (Table 2) . DPDPE inhibits the binding of 13H1DIP to intact cells with a K of 14.5 nM, and its inhibitory potency is significantly reduced, as in the studies on membrane preparations, by the presence of 100 mM NaCl in the incubation medium (Table 3) .
Opioid inhibition of CAMP accumulation in Gin-1 cells
The effect of DPDPE on the activation of adenyl cyclase induced by different stimuli was studied in GTl-1 cells by measuring the intracellular accumulation of CAMP. As illustrated in Fig. 5 , the basal levels of CAMP found in control cells were not modified by a lo-PM concentration of the ii-opioid agonist DPDPE. The addition to GTI-1 cells of 1 PM PGE, dramatically enhanced CAMP accumulation (8.6fold over prestimulated levels at the end of the 15 mm of treatment). PGE, also showed a strong stimulatory effect on CAMP accumulation. However, the stimulatory effects on the intracellular CAMP concentration induced by both PGE, and PG-treated cells.
PGE, were significantly reduced by coincubation with 10 PM DPDPE by 44% and 33% respectively (Fig. 5 ).
Discussion
The results described in the present study provide the first evidence showing that LHRH-producing GTl-1 cells express opioid receptors. The nonselective opioid antagonist [3HlDIP binds with high affinity (0.2 nM) to both crude cell membrane preparations as well as intact GTl-1 cells. The binding affinity of [3H]DIP to GTl-1 cells is similar to that reported for this opiate when tested on membrane preparations obtained from either rat brain or neuroblastoma cells (26, (32) (33) (34) (35) .
The binding of 13H]DIP to GTl-1 cells is characterized by low nonspecific binding and is similar to that observed in crude membrane preparations of whole mouse brain. fH]DIP binds with approximately equal affinity to F-, 6, and fc-opioid receptors (22, 32, 36) ; consequently, it is not possible to discriminate, using only this approach, the type(s) of opioid receptor(s) present on GTl-1 cells. Selective displacement experiments performed with specific opioid ligands revealed the presence only of binding sites of the 6 type. Indeed, in the membrane preparation studies, the selective ligand for S-opioid receptors, DPDPE, strongly inhibits (>90% at 1 PM) the binding of 13HlDIP, which, on the contrary, is not affected by selective ligands for the k-and K-opioid-binding sites. The K, for DPDPE (5.5 nM) calculated on the present results is very similar to the K, or & found for labeled DPDPE on 6 sites present in membrane preparations obtained from rodent brain or neuroblastoma cells (35,37-39). The presence of only binding sites of the 6 type was also confirmed in intact GTI-1 cells (see below).
A further characterization of these receptors was performed by analyzing their sensitivity to sodium ions. It is well known that the binding of CL-and &agonists is decreased in the presence of sodium ions, a phenomenon that does not occur when opioid antagonists are used. From the data obtained, it is evident that the presence of sodium in the incubation buffer induces a significant decrease in the potency of DPDPE to inhibit the binding of [3H]DIP to either membrane preparations or intact GTI-1 cells. This results in increases in the Ki and IC,,.
As previously mentioned, the presence of 6-opioidbinding sites was confirmed when the binding experiments were repeated on intact GTl-1 cells. However, the selective inhibitory effect of the 6-ligand DPDPE on the binding of [3H]DIP was slightly lower in intact GTl-1 cells than that found in crude membrane preparations.
It is well known that the binding of p-and a-agonists is decreased not only in the presence of sodium ions, but also by GTP (34). As the binding experiments on intact GTl-1 cells were performed in a sodium-free buffer, it is possible that the decreased displacing activity of DPDPE might be due to the presence of GTP or to a combined effect of GTP and residual intracellular sodium (31). Recently, the cloning of b-opioid receptors has been reported (40-42); an assessment of the expression of messenger RNA for the &opioid receptors in GTI-1 cells is presently under way and will provide a definitive evidence of their presence in these LHRH-secreting cells. It is well known that opioids may exert inhibitory effects on the stimulated accumulation of CAMP in several cells and tissues (23, 43, 44) . To investigate whether the 6-opioid receptors identified on GTl-1 cells are functional, the ability of the &agonist DPDPE to inhibit the stimulation of CAMP accumulation induced in GTl-1 cells by treatment with two known activators of adenylyl cyclase, PGE, and PGE,, was analyzed (45). The results obtained clearly showed that both PGs are strong stimulators of CAMP accumulation in GTl-1 cells, and that the activation of Gopioid receptors by DPDPE leads to a significant decrease in the stimulated CAMP levels. The data presented here are consistent with the numerous observations of an inhibitory role exerted by the opioids on intracellular CAMP accumulation (43-47) and indicate that the &receptors reported on GTI-1 cells are functional. In addition, the ability to inhibit CAMP accumulation as well as the sensitivity to sodium ions suggest a functional coupling of the &receptor subtype present in GTl-1 cells to intracellular effector molecules such as the GTP-binding proteins (22, 23) . In experiments presently in progress, it has been shown that the S-opioid agonist DPDPE inhibits LHRH secretion in GTl-1 cells elicited by forskolin (Maggi, R., F. Pimpinelli, L. Martini, and F. Piva, in preparation).
The presence of opioid-binding sites on the subclone of GTl cells used in the present experiments is relevant, especially in light of the possible role of these receptors in the control of LHRH release and expression. If one assumes that GTl cells represent a good model for the study of LHRHsecreting neurons, the obvious conclusion from these data is that endogenous opioid peptides may influence LHRH secretion by acting directly on LHRH-secreting neurons. A second conclusion would be that this effect of the opioids is mediated by the &subclass of receptors. Obviously, it must be pointed out that the present data do not exclude the possibility that opioids act on the release of LHRH via other mechanisms (see below). As mentioned in the introduction, a large body of evidence implicates opioid peptides in the central mechanisms controlling gonadotropins and LHRH secretion (1, 15, (17) (18) (19) (20) . The prevailing theory proposes that opioid neurons have synaptic contacts with intermediate neurons, which, in turn, influence LHRH neurons via the local release of their respective neurotransmitters (18, 48) . However, a few reports have demonstrated that, at least in rats (4951), monkeys (52), and cows (53), opioid neurons (particularly POMC or /.3-endorphin reactive) may entertain direct synaptic contacts with hypothalamic LHRH-immunoreactive neurons, suggesting the possibility of a direct effect of physiological opioids. In contradistinction with the present data, which shows the presence of &receptors on LHRH-producing neurons, a number of data obtained in viva, especially in the rat, support the view that opioids affect LHRH release mainly through the interaction with opioid receptors of the p type (54-57). However, a few studies have also implicated 6 (58-60)-and K (58,59)-receptors in such a mechanism. For instance, Leadem et aZ. (58, 59 ) have shown that A-agonists, including DPDPE, induce a biphasic effect on LH secretion in ovariectomized rats after intraventricular injection. In this connection, one may also point out that /.3-endorphin binds with similar affinities to p and 6 sites (22, 36) . It must be recalled that the relative proportions of opioid receptor subtypes are different in the brains of various animal species (61). For instance, in the forebrain of the mouse (the species from which GTl cells are derived), there is 25% more &receptor and 40% less p-receptor than in the forebrain of the rat, suggesting a predominantly &receptor composition in the mouse brain (61). Moreover, in the mouse, both the hypothalamus and preoptic area contain the same amounts of p-and Gopioid receptors (62), whereas in the rat, the concentration of A sites is extremely low in the hypothalamus (39, 61, 63), a structure in which a relatively high concentration of p-receptors is present in this species (61, 63) .
In conclusion, from the data here presented, when analyzed in conjunction with the evidence just described, we hypothesize that the effects of physiological opioid peptides on LHRH secretion consist of two distinct components: the first, acting directly on the &receptors present on the LHRHsynthesizing neurons, and the second acting via intermediate neurons, where opioids probably interact mainly with the F-receptor subfamily. 
